image
Akebia Therapeutics, Inc. AKBA
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 1.83
-1.08 %
$ 399 M
Market Cap
-8.32
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one AKBA stock under the worst case scenario is HIDDEN Compared to the current market price of 1.83 USD, Akebia Therapeutics, Inc. is HIDDEN

AKBA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one AKBA stock under the base case scenario is HIDDEN Compared to the current market price of 1.83 USD, Akebia Therapeutics, Inc. is HIDDEN

AKBA Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one AKBA stock under the best case scenario is HIDDEN Compared to the current market price of 1.83 USD, Akebia Therapeutics, Inc. is HIDDEN

AKBA Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart AKBA

image
1M -22%
6M 18%
1Y 13%
3Y -32%
5Y -413%
All
$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.215 Sep15 SepOct '24Oct '2415 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 Feb
FINANCIALS
195 M REVENUE
-33.49%
Growth Rates
1Year -33.49%
3Years -12.98%
5Years -1.30%
7Years 99.73%
10Years 0.00%
-46.3 M OPERATING INCOME
26.79%
Growth Rates
1Year 26.79%
3Years 50.28%
5Years 23.64%
7Years 14.32%
10Years -11.25%
-51.9 M NET INCOME
43.90%
Growth Rates
1Year 43.90%
3Years 48.65%
5Years 18.41%
7Years 12.83%
10Years -14.71%
-23.4 M OPERATING CASH FLOW
68.03%
Growth Rates
1Year 68.03%
3Years 40.39%
5Years 24.84%
7Years -4.97%
10Years -7.51%
0 INVESTING CASH FLOW
100.00%
Growth Rates
1Year 100.00%
3Years 25.99%
5Years 0.00%
7Years 0.00%
10Years 7.18%
-25.2 M FINANCING CASH FLOW
-172.67%
Growth Rates
1Year -172.67%
3Years -3.50%
5Years -4.75%
7Years -4.67%
10Years -4.78%
37.4 M REVENUE
-14.25%
Growth Rates
1Year -33.49%
3Years -12.98%
5Years -1.30%
7Years 99.73%
10Years 0.00%
-12.5 M OPERATING INCOME
-43.32%
Growth Rates
1Year 26.79%
3Years 50.28%
5Years 23.64%
7Years 14.32%
10Years -11.25%
-20 M NET INCOME
-133.50%
Growth Rates
1Year 43.90%
3Years 48.65%
5Years 18.41%
7Years 12.83%
10Years -14.71%
-6.7 M OPERATING CASH FLOW
33.49%
Growth Rates
1Year 68.03%
3Years 40.39%
5Years 24.84%
7Years -4.97%
10Years -7.51%
-2 K INVESTING CASH FLOW
93.10%
Growth Rates
1Year 100.00%
3Years 25.99%
5Years 0.00%
7Years 0.00%
10Years 7.18%
1.22 M FINANCING CASH FLOW
-83.99%
Growth Rates
1Year -172.67%
3Years -3.50%
5Years -4.75%
7Years -4.67%
10Years -4.78%
Balance Sheet Akebia Therapeutics, Inc.
image
Current Assets 118 M
Cash & Short-Term Investments 42.9 M
Receivables 39.3 M
Other Current Assets 35.9 M
Non-Current Assets 124 M
Long-Term Investments 0
PP&E 16 M
Other Non-Current Assets 108 M
17.76 %16.26 %14.87 %6.64 %44.48 %Total Assets$241.7m
Current Liabilities 99.9 M
Accounts Payable 14.6 M
Short-Term Debt 24 M
Other Current Liabilities 61.2 M
Non-Current Liabilities 172 M
Long-Term Debt 80.1 M
Other Non-Current Liabilities 92.3 M
5.37 %8.83 %22.47 %29.43 %33.89 %Total Liabilities$272.3m
EFFICIENCY
Earnings Waterfall Akebia Therapeutics, Inc.
image
Revenue 195 M
Cost Of Revenue 74.1 M
Gross Profit 120 M
Operating Expenses 167 M
Operating Income -46.3 M
Other Expenses 5.67 M
Net Income -51.9 M
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)195m(74m)120m(167m)(46m)(6m)(52m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
61.90% GROSS MARGIN
61.90%
Averages
1Year 61.90%
3Years 53.70%
5Years 43.50%
7Years 59.07%
10Years -702.95%
-23.77% OPERATING MARGIN
-23.77%
Averages
1Year -23.77%
3Years -56.53%
5Years -76.50%
7Years -73.31%
10Years -940.31%
-26.68% NET MARGIN
-26.68%
Averages
1Year -26.68%
3Years -59.19%
5Years -75.90%
7Years -72.21%
10Years -934.89%
169.78% ROE
169.78%
Averages
1Year 169.78%
3Years -428.42%
5Years -299.48%
7Years -226.98%
10Years -187.01%
-21.48% ROA
-21.48%
Averages
1Year -21.48%
3Years -32.74%
5Years -37.76%
7Years -32.45%
10Years -34.82%
-27.89% ROIC
-27.89%
Averages
1Year -27.89%
3Years -39.05%
5Years -48.14%
7Years -42.24%
10Years -45.13%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Akebia Therapeutics, Inc.
image
100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20152015201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -51.9 M
Depreciation & Amortization 41.8 M
Capital Expenditures 0
Stock-Based Compensation 9.32 M
Change in Working Capital -20.7 M
Others -15.8 M
Free Cash Flow -23.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Akebia Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for AKBA of $6 , with forecasts ranging from a low of $6 to a high of $6 .
AKBA Lowest Price Target Wall Street Target
6 USD 227.87%
AKBA Average Price Target Wall Street Target
6 USD 227.87%
AKBA Highest Price Target Wall Street Target
6 USD 227.87%
Price
Max Price Target
Min Price Target
Average Price Target
66554433221100Apr '24Apr '24May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25May '25May '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Akebia Therapeutics, Inc.
image
Sold
0-3 MONTHS
589 K USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
265 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Akebia Therapeutics: Still Bullish On Vafseo As Auryxia's Revenues Decline Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia's declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA's signature HIF pathway. So far, it has shown some early successes, which makes me optimistic. AKBA is also working on a Phase 3 trial for non‑dialysis CKD patients, which is scheduled for mid‑2025 to support a potential label expansion. seekingalpha.com - 3 weeks ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted seven newly-hired employees options to purchase an aggregate of 130,763 shares of Akebia's common stock on January 31, 2025. The options were granted as an inducement material to teach employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 3 weeks ago
Akebia Therapeutics Announces Multiple Positive Business Updates New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Vafseo tablets now shipping in the U.S. Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients Company to discuss business updates at 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. prnewswire.com - 1 month ago
New Strong Sell Stocks for January 3rd AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024. zacks.com - 1 month ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. , Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on December 31, 2024. prnewswire.com - 1 month ago
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ --  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 43rd Annual J.P. prnewswire.com - 2 months ago
New Strong Sell Stocks for December 5th AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024. zacks.com - 2 months ago
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted nine newly-hired employees options to purchase an aggregate of 121,000 shares of Akebia's common stock on November 29, 2024. prnewswire.com - 2 months ago
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current standard of care CAMBRIDGE, Mass. , Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late November U.S. Renal Care (USRC) enrolled the first patient in its Vafseo® (vadadustat) Outcomes In-Center Experience (VOICE) collaborative trial. prnewswire.com - 2 months ago
New Strong Sell Stocks for November 27th AKBA, ABG and CLH have been added to the Zacks Rank #5 (Strong Sell) List on November 27, 2024. zacks.com - 3 months ago
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference CAMBRIDGE, Mass. , Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3 rd at 10:30 AM EST. prnewswire.com - 3 months ago
New Strong Sell Stocks for November 22nd ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024. zacks.com - 3 months ago
8. Profile Summary

Akebia Therapeutics, Inc. AKBA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 399 M
Dividend Yield 0.00%
Description Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Contact 245 First Street, Cambridge, MA, 02142 https://www.akebia.com
IPO Date March 20, 2014
Employees 167
Officers Mr. Richard C. Malabre Chief Accounting Officer Ms. Tracey Vetterick Vice President of Portfolio Strategy & Corporate Administration Mr. John P. Butler MBA Chief Executive Officer, President & Director Mr. Erik John Ostrowski M.B.A. Senior Vice President, Chief Financial Officer & Chief Business Officer Dr. Steven Keith Burke M.D. Senior Vice President of Research & Development and Chief Medical Officer Ms. Kimberly Garko Senior Vice President & Chief Technical Officer Mr. Nicholas Grund Senior Vice President & Chief Commercial Officer Mercedes Carrasco Senior Director of Investor & Corporate Communications Ms. Meredith Bowman Senior Vice President & Chief People Officer Ms. Carolyn Rucci Senior Vice President of Legal, General Counsel & Secretary